Exploration of Resveratrol Derivatives as Novel Therapeutic Modulators of 11β-Hydroxysteroid Dehydrogenase 1 Activity in Metabolic Dysregulation
The resveratrol cis-dehydrodimer represents a viable candidate for further experimental validation as a therapeutic agent for metabolic disorders. Future studies should include synthetic validation and in vivo testing to confirm its efficacy.
Authors
- Guojun Zheng (ORCID: https://orcid.org/0000-0001-9204-2694)
- Mohammed Bourhia (ORCID: https://orcid.org/0000-0003-3707-8461)
- Yousef A. Bin Jardan (ORCID: https://orcid.org/0000-0003-3302-4036)
- Jaouad Bensalah (ORCID: https://orcid.org/0000-0001-5758-3559)
- Musaab Dauelbait (ORCID: https://orcid.org/0009-0003-0685-8243)
- Muhammad Shahab (ORCID: https://orcid.org/0000-0002-4437-0711)
Institutions
- King Saud University (SA)
- Université Ibn-Tofail (MA)
- Université Ibn Zohr (MA)
- University of Bahri (SD)
- Beijing University of Chemical Technology (CN)
Publication Details
- Journal
- Current Medicinal Chemistry
- Published
- 2025-07-30
- DOI
- https://doi.org/10.2174/0109298673376734250707194939
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00